An Interview with Sander Slootweg, Forbion Capital Partners: Insights from BIO-Europe® 2015

**[YouTube Video Description Rewrite – Optimized for SEO]**

Welcome to BIO-Europe® 2015! In this video, Mike Ward, the global director of content for Informa Pharma Insights, interviews Sander Slootweg, the managing partner at Forbion Capital Partners, about their new EUR 120m+ fund dedicated to life science projects. They discuss the fund’s geographical focus, potential companies of interest, and successful exit strategies[^1^].

Forbion Capital Partners is currently in the process of raising their new fund, with a target of reaching EUR 150-200 million by the end of the year[^1^]. The fund’s investment focus will continue to be on biopharma (70%), med tech (30%), and diagnostics[^1^]. They invest in both early-stage and late-stage companies in the life sciences sector, aiming to facilitate commercial rollouts of products in Europe[^1^].

Sander Slootweg discusses the geographical focus of their investments, historically having a focus on North America and Europe, including Canada[^1^]. They have seen a shift in their limited partners, attracting investment from wealthy families and benefiting from European investment funds and local initiatives[^1^]. The firm has a stable investor base, with many returning limited partners[^1^].

In terms of their investment strategy, Forbion Capital Partners typically takes a leading role in syndicates and investments, either as the lead investor or a co-lead investor[^1^]. They are actively involved in setting up companies and projects, partnering with virtual development structures and established management teams[^1^].

When it comes to exit strategies, Forbion Capital Partners aims to shorten the cycle of repayments to investors by strategically timing their investments[^1^]. They strive to provide financial success while contributing to patients’ lives through innovative medical solutions[^1^].

Watch the full interview to learn more about Forbion Capital Partners and their investment strategies in the life sciences sector![^1^]

For more informative videos and articles, visit [Partnering360]( [^1^]. To learn more about BIO-Europe, visit their [website]( for additional information[^1^].

**Tags/Keywords:** BIO-Europe® 2015, EBD Group, Informa Business Intelligence, Mike Ward, pharma, biotech, drug development, business development, partnerships, Sander Slootweg, Forbion Capital Partners, venture capital, VCs, exit strategies, Health.


[^1^] [Video transcript source](

Sander Slootweg, managing partner at Forbion Captial Partners, speaks to Mike Ward, global director of content for Informa Pharma Insights, at the recent BIO-Europe partnering meeting in Munich, Germany, about the venture capitalist’s new EUR 120m+ fund dedicated to life science projects. They discuss geographical focus for the cash, potential companies of interest and successful exit strategies.
Find more videos and articles at

For more information on BIO-Europe, visit our webpage:

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Union Minister Pradhan Commends UGC’s Efforts in Enhancing Higher Education Quality in the Country

My Journey: Confronting Cancer